StockData

Relay Therapeutics vs Surrozen

RLAY and SRZN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How RLAY and SRZN compare

Relay Therapeutics is the larger company, worth 10 times as much as Surrozen ($3.6B against $352M).

Relay Therapeutics grew revenue faster over the last twelve months (23.9% versus −8.8% for Surrozen).

Relay Therapeutics keeps more of each dollar of sales as profit, with a net margin of −2764% compared with −2885% at Surrozen.

Relay Therapeutics scores higher on the StockData Score (10 against 5 for Surrozen), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricRLAYSRZN
Size and price
Market cap$3.6B$352M
Share price$16.47$29.98
Change, 1 year162%131%
Change, 5 years−44.8%−77.8%
Beta (5Y)1.961.88
Employees19244
StockData Score
Total score10 (better)5
Valuation score00
Growth score2 (better)0
Performance score2 (better)0
Health score6 (better)5
Dividend score00
Valuation
P/S349×30.6× (better)
P/B4.1×–
FCF yield–−9.9%
Growth
Revenue growth (TTM)23.9% (better)−8.8%
Revenue growth, 5Y average−28.6%–
Profitability
Operating margin−2999%−385% (better)
Net margin−2764% (better)−2885%
FCF margin–−304%
Return on equity−36.8%–
Return on invested capital−37.1%–
Financial health
Debt / equity0.00–
Current ratio18.27 (better)12.14
Altman Z-score24.86 (better)−6.81
Piotroski F-score4 (better)3
Dividends and buybacks
Buyback yield–−0.99%
Shareholder yield0.00% (better)−0.99%
Ownership
Held by institutions113%91.3%
Held by insiders24.5%44.5%
Insider net buying, 12 months−$129M$1.6M (better)
Superinvestors holding1–
Short interest, % of float26.4%49.6%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.